ABBV vs MRK
AbbVie Inc. and Merck & Co. Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ABBV | MRK |
|---|---|---|
| Revenue | $61.2B | $65.0B |
| Net income | $4.2B | $18.3B |
| Gross margin | 70.2% | 74.8% |
| Net margin | 6.9% | 28.1% |
| Return on equity | 15367.3% | 36.9% |
| Diluted EPS | $2.36 | $7.28 |
| Dividend / share | $6.65 | $3.28 |
| Payout ratio | 275.8% | 44.8% |
| Free cash flow | $17.8B | $12.4B |
| Equity | $-3.3B | $52.6B |
| Net debt / equity | 16.49× | 0.66× |
| Current ratio | 0.67× | 1.54× |
| Revenue CAGR 5y | 6.0% | 9.4% |
| Profit CAGR 5y | −1.7% | 20.9% |
ABBV and MRK book revenue within 15% of each other, and MRK keeps more of each dollar of revenue as profit (28.1% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ABBV | MRK |
|---|---|---|
| FY2025 | $61.2B | $65.0B |
| FY2024 | $56.3B | $64.2B |
| FY2023 | $54.3B | $60.1B |
| FY2022 | $58.1B | $59.3B |
| FY2021 | $56.2B | $48.7B |
| FY2020 | $45.8B | $41.5B |
| FY2019 | $33.3B | $39.1B |
| FY2018 | $32.8B | $42.3B |
| FY2017 | $28.2B | $40.1B |
| FY2016 | $25.6B | $39.8B |
Net income by year
Bottom line
| Fiscal year | ABBV | MRK |
|---|---|---|
| FY2025 | $4.2B | $18.3B |
| FY2024 | $4.3B | $17.1B |
| FY2023 | $4.9B | $365.0M |
| FY2022 | $11.8B | $14.5B |
| FY2021 | $11.5B | $13.0B |
| FY2020 | $4.6B | $7.1B |
| FY2019 | $7.9B | $9.8B |
| FY2018 | $5.7B | $6.2B |
| FY2017 | $5.3B | $2.4B |
| FY2016 | $6.0B | $3.9B |
Advertisement
AdSense · Rectangle 336×280